Skip to content
    INO
    Earnings call· Jun 2026(Q2 FY26)

    INOVIO PHARMACEUTICALS Q2 FY26 earnings call INO

    Aug 12, 2026 Source

    Executive summary

    Inovio Q2 FY26 — INO-3107 BLA Progress and Launch Preparations

    Inovio is nearing a critical juncture with its lead candidate, INO-3107, for RRP, as the BLA review progresses towards an October PDUFA date. The company has strengthened its financial position to support a potential launch, while also advancing its broader pipeline through strategic partnerships. Management remains focused on addressing the significant unmet need in RRP with a differentiated product profile, despite the FDA's ongoing review of accelerated approval eligibility.

    Highlights

    5

    • INO-3107 BLA review advanced with late cycle meeting and pre-licensure inspections completed, on track for October 30, 2026 PDUFA date.

    • Equity offering raised $18.3 million in net proceeds, extending cash runway into late Q1 2027 and through potential INO-3107 launch.

    • ApolloBio, partner for VGX-3100, announced positive top-line Phase 3 results for cervical dysplasia, meeting primary efficacy endpoint.

    • Operating expenses decreased by 19% to $18.6 million in Q2 2026 and 16% in H1 2026, reflecting strategic resource management.

    • Net loss significantly reduced to $6 million ($0.07 per share) in Q2 2026 from $23.5 million ($0.61 per share) in Q2 2025.

    Concerns

    2

    • FDA did not discuss preliminary conclusion regarding accelerated approval eligibility for INO-3107 during the informal clinical meeting.

    • FDA's feedback on the confirmatory trial design for INO-3107 is still pending.

    Guidance & targets

    4
    CategoryTargetConfidence
    INO-3107 BLA PDUFA Target Date
    October 30, 2026
    high materiality
    High
    Cash Runway
    Into late first quarter 2027
    high materiality
    High
    Operational Net Cash Burn
    Approximately $18 million
    medium materiality
    High
    Orphan Drug Market Exclusivity
    7 years
    high materiality
    High

    Operational metrics

    10
    Cash, cash equivalents and short-term investments
    $36.7Mdown from $58.5M as of Dec 31, 2025
    Q2 FY26

    Balance as of June 30, 2026.

    Net proceeds from equity offering
    $18.3M
    July 2026

    After deducting underwriter discounts, commissions, and operating expenses.

    Operating expenses
    $18.6Mdown 19% YoY from $23.1M in Q2 FY25
    Q2 FY26

    Reflects ongoing strategic efforts to manage resources.

    Operating expenses reduction
    16%vs same period last year
    H1 FY26

    Due to ongoing strategic efforts to manage resources to support progression of the 3107 program.

    Net loss
    $6Mvs $23.5M in Q2 FY25
    Q2 FY26

    Primarily driven by a non-cash gain on fair value adjustment related to warrant liabilities.

    Net loss per share (basic and dilutive)
    $0.07vs $0.61 in Q2 FY25
    Q2 FY26

    Reflects the decrease in net loss.

    Non-cash gain on fair value adjustment
    $9M
    Q2 FY26

    Related to warrant liabilities, contributing to the decrease in net loss.

    RRP patient penetration (competitor)
    low single-digit
    Current

    Refers to the early uptake of [Papzimios] among the prevalent RRP population.

    Patients treated with competitor (Papzimios)
    approximately 200
    Early uptake

    Indicates early uptake of [Papzimios].

    Competitor (Papzimios) patients requiring MRD surgery during dosing
    83%
    Phase 1/2 trial

    Percentage of participants in the Phase 1/2 trial for [Papzimios] who required at least one MRD surgery during the dosing window.

    Industry KPIs

    3
    MetricValueDetails
    Pipeline read out calendarOctober 30, 2026 PDUFA date for INO-3107; Positive Phase 3 results for VGX-3100
    Regulatory approvals filingsBLA review for INO-3107 ongoing; ApolloBio plans regulatory filing for VGX-3100 in China
    Clinical trial efficacy safety dataVGX-3100 met primary efficacy endpoint of CIN2 or CIN3 lesion regression and HPV 16 and 18 viral clearance; favorable safety and tolerability profile.

    Deals & partnerships

    2
    Syneos HealthContract sales organization to support U.S. commercialization of INO-3107.

    Syneos Health has deep experience in rare disease launches and will serve as Inovio's CSO.

    ApolloBioPartner for VGX-3100 in Greater China.

    ApolloBio recently announced positive top-line Phase 3 results for VGX-3100 for cervical dysplasia and plans to seek regulatory approval in China.

    Risks & headwinds

    3
    FDA not discussing accelerated approval eligibilityDuring July 2026 informal clinical meeting

    Not quantified

    Mitigation: Management believes INO-3107 meets criteria for accelerated approval based on efficacy, tolerability, and differentiated MOA, and continues to engage with FDA.

    Pending FDA feedback on confirmatory trial designOngoing

    Not quantified

    Mitigation: Management expects comments to be forthcoming and does not believe it will impact approvability or PDUFA date.

    Competition from existing treatmentsCurrent

    Early uptake of [Papzimios] with approximately 200 patients treated, representing low single-digit penetration.

    Mitigation: INO-3107 is positioned with competitive advantages, including not requiring additional surgery during dosing, differentiated MOA, and no ultra-cold chain handling.

    What to watch in Q3 FY26

    5

    INO-3107 BLA Decision

    October 30, 2026
    CurrentOn track for PDUFA date
    TargetFDA approval or other regulatory decision

    Why it matters

    This is the primary catalyst for INO-3107, determining its market entry and the company's future trajectory.

    We are on track for the October 30 target PDUFA date.

    Q&A highlights

    4

    Were any new efficacy, safety, or CMC-related questions raised by the FDA during the informal clinical meeting?

    Mike Sumner stated that the FDA did not raise new questions on efficacy, safety, or CMC. They had previously received all data. The FDA did not comment on accelerated approval eligibility, as the file is under active review.

    “They certainly have not disagreed with our positioning in terms of how we've presented our efficacy and safety data. But unfortunately, as you heard me say, they weren't in a position to comment on the eligibility question as the file is under active review.”

    asked by [ Lien Chan ] from Jefferies · answered by Mike Sumner

    2 min read5 chapters

    Detailed Narrative

    01

    INO-3107 Regulatory Progress

    The FDA's review of the BLA for INO-3107 is on track for an October 30, 2026 PDUFA date. Key milestones completed include the late cycle review meeting and all scheduled pre-licensure inspections (clinical, drug manufacturing, in-house drug testing, and delivery device facility), with only one reported observation that has been addressed. An informal clinical meeting was held in July where Inovio presented the totality of data supporting INO-3107's safety and efficacy, though the FDA did not comment on accelerated approval eligibility.

    02

    Commercial Launch Preparations

    Inovio is actively building its critical launch infrastructure for INO-3107, leveraging experienced field teams. Syneos Health has been engaged as the contract sales organization for U.S. commercialization, and targeted marketing efforts are planned with an agency of record and a hub partner for patient support. These preparations aim to establish payer and hospital access, drive healthcare provider and patient preference, and educate the market about INO-3107's potential.

    03

    Differentiated Product Profile of INO-3107

    INO-3107 is positioned as a potential new standard of care for RRP due to its differentiated profile. It treats RRP without requiring additional scoping and surgeries during the dosing window, unlike existing treatments where 83% of participants required at least one MRD surgery. The product also avoids potential impacts from immunosuppressive papilloma microenvironments or pre-existing neutralizing antibodies and does not require specialized ultra-cold chain handling, offering greater flexibility in care settings.

    04

    Pipeline Advancements through Partnerships

    Inovio continues to advance its broader pipeline through strategic collaborations. ApolloBio, its partner for VGX-3100 in Greater China, announced positive top-line Phase 3 results for cervical dysplasia, meeting the primary efficacy endpoint and demonstrating a favorable safety profile. ApolloBio plans to seek regulatory approval in China. Additionally, Inovio presented promising preclinical data on its next-generation DNA-encoded protein (D-Prop) technology for hemophilia A and is exploring partnerships to advance D-Prop candidates for rare diseases like Fabry disease and hypophosphatasia.

    05

    Financial Position and Cash Runway

    The company strengthened its balance sheet with a July 2026 equity offering, generating approximately $18.3 million in net proceeds. This extends the estimated cash runway into late first quarter 2027, covering a potential launch of INO-3107. Operating expenses decreased by 19% year-over-year to $18.6 million in Q2 2026 and by 16% for the first six months of 2026, reflecting strategic resource management. The net loss significantly improved to $6 million ($0.07 per share) in Q2 2026, compared to $23.5 million ($0.61 per share) in Q2 2025, partly due to a non-cash gain on warrant liabilities.

    AI-generated summary of the company’s earnings call. Not investment advice.